Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Jabookie75on Mar 28, 2019 8:53am
63 Views
Post# 29546889

RE:Can we all please relax about the bloody PP.

RE:Can we all please relax about the bloody PP.Nails, for all the amazing DD and the amount of shares you hold and your constant contact with JHT, I'm just sad you never even got a chance to get more cheap shares.  

Anyway, I'm still on the sidelines for now and booked my profits at 0.145 from 0.04.  These two tranches tell me that Q4 2018 numbers are not going to be good (which we all excpect) and Q1, 2019 might not be great either if they are collecting $2 million in late Feb just to keep going.  They are still clearly nowhere near being cash flow positive.

Sure their might be a NR that rockets this thing and I am willing to pay more to get back in if I have to.  But we all know JHT's track record is not great and this is a show me stock.  True growth in share price will not happen until we have concrete numbers that show growth.  The market is skeptical, as they should be, given the history of this company.  I felt the need to book my profits and reduce my risk here in case there is a sell off due further poor numbers which is a real possibility.  For me, Q2, 2019 is when they better show big time growth and they need to be well on their way to the $30 million in revenue they are forecasting.  

I'm sure I will get the basher reply from DobreCafe.  Go ahead.  I've been here for years and was buying this stock over $1 and rode it all the way down to 0.01.  I am highly skeptical of JHT and I reduced my exposure and have no regrets as I have my profits secured.  I have dry powder ready to rejoin when the growth is clearly shown to all of us in CONCRETE NUMBERS and not speculation and forecasts.  Good luck to all of you.

Cheers,

Jay

Nailbiter1 wrote:
Email received from Tripp Yesterday.

Hello James.
What was the opening date for the .05 cent PP offering?
Thanks.

------------------------------------------- REPLY

As usual, a small group of guys are off on a tangent.
The PP was launched in mid Feb when the share price was $0.05\0.06. It was filled within days. Tranche #2 was launched right after because there was so much demand and the new 5-day VWAP put the pricing at $0.08. So, share price still low.
The surge in share price is precisely because we have kept on marketing the company to the mostly new investors. It is their interest that has generated the momentum.
The deals have been long filled. It is the paperwork that has taken time.
James R Howard-Tripp,
Chairman and CEO,
GeneNews Ltd.


Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse